Disease Overview：Aortic regurgitation（AR）
Aortic regurgitation (AR), also known as aortic insufficiency, is a valvular heart disease characterized by incomplete closure of the aortic valve during diastole, resulting in retrograde blood flow from the aorta into the left ventricle. This chronic volume overload leads to progressive left ventricular dilation and hypertrophy, eventually impairing systolic function and increasing risk of heart failure, arrhythmias, and sudden cardiac death. Etiologies include degenerative valve disease, bicuspid aortic valve, infective endocarditis, aortic root dilation (e.g., Marfan syndrome or annuloaortic ectasia), and rheumatic heart disease. Diagnosis relies on transthoracic echocardiography—assessing regurgitant jet size, vena contracta width, pressure half-time, and left ventricular dimensions—and may be supplemented by cardiac MRI for precise quantification of regurgitant fraction and ventricular remodeling. Clinical management ranges from serial monitoring in asymptomatic mild-to-moderate cases to timely surgical intervention—typically aortic valve replacement (AVR) via sternotomy or transcatheter aortic valve implantation (TAVI)—in severe symptomatic or high-risk asymptomatic patients meeting guideline-based criteria.
China offers compelling advantages for international patients seeking treatment for aortic regurgitation. The country hosts numerous nationally accredited cardiovascular centers with internationally trained cardiothoracic surgeons and interventional cardiologists who routinely perform high-volume, complex AVR and TAVI procedures—many certified by the European Association for Cardio-Thoracic Surgery (EACTS) or American College of Cardiology (ACC). Advanced imaging platforms—including 3D/4D echocardiography, ultra-high-field cardiac MRI, and fusion-guided TAVI planning—are standard at tier-1 hospitals. Published outcomes demonstrate 30-day mortality rates <2% for surgical AVR and procedural success >97% for TAVI in eligible patients, consistent with Western benchmarks. Crucially, costs for comprehensive care—including diagnostics, surgery, hospitalization, and follow-up—are typically 40–60% lower than in the US, UK, or Germany, without compromising clinical quality or regulatory oversight (all procedures adhere to China NMPA and ISO 13485 standards).
As a dedicated medical tourism agency, we facilitate seamless access to this high-value care for international patients. We coordinate pre-travel consultations, verify physician credentials and hospital accreditations, arrange appointments at vetted cardiovascular centers, provide transparent, all-inclusive pricing with no hidden fees, assist with visa documentation and travel logistics, and assign bilingual case managers for continuous support—from initial evaluation through postoperative recovery and discharge planning.
Aortic regurgitation: treatment in China helps patients compare specialist hospitals, initial assessment steps and estimated costs that may vary by city, institution and clinical condition.
Medical Treatment Guide
Treatment Options & Itemized Cost Breakdown: Aortic Regurgitation (Cardiovascular Department)
I. Non-Surgical / Conservative Management
*Indicated for asymptomatic mild-to-moderate AR, preserved LVEF (>50%), and stable LV size (LVEDD <65 mm).*
- •Medications:
- Beta-blockers (e.g., bisoprolol): $8–$22/month - Diuretics (e.g., furosemide) if volume overload: $4–$15/month
- •Monitoring:
- BNP/NT-proBNP assay: $24–$42 - Annual Holter + exercise stress test: $95–$160 - Routine labs (renal function, electrolytes, CBC): $32–$58
II. Surgical & Interventional Options
*Eligibility: Symptomatic severe AR, LVEF ≤50%, LVEDD ≥65 mm, or progressive LV dilation despite medical therapy.*
- •Surgical Aortic Valve Replacement (SAVR):
- Bioprosthetic valve (e.g., Edwards Perimount): $10,800–$14,300
- •Transcatheter Aortic Valve Replacement (TAVR):
- Self-expanding (e.g., Medtronic Evolut PRO+): $18,900–$23,700
- •Preoperative Workup (mandatory):
- CT aortography (valve sizing + access assessment): $1,050–$1,630 - Pulmonary function test + carotid duplex: $380–$620
III. Special/Complex Scenarios
- •AR with ascending aorta >50 mm or rapid dilation (>3 mm/year): Combined aortic root replacement (Bentall procedure): $15,400–$19,800
- •Active endocarditis with valve destruction: Urgent SAVR + prolonged IV antibiotics (4–6 weeks): $12,900–$17,200 (includes ICU stay, blood cultures, TEE)
- •Renal failure (eGFR <30 mL/min): TAVR preferred; dialysis coordination adds $1,800–$2,600
IV. Quick Selection Guide
- •<65 years, no comorbidities, high activity demand: Mechanical SAVR — durable, cost-effective long-term ($8,200), lifelong anticoagulation required.
- •≥75 years, frailty/comorbidities (COPD, CKD): TAVR — lower perioperative risk, faster recovery ($17,600–$23,700); avoids sternotomy.
- •Moderate AR, age 50–70, borderline LV dilation: Conservative + strict 6-month echo surveillance — total annual cost $1,400–$2,300, defers intervention.
- •Severe AR + Marfan syndrome or bicuspid aorta: SAVR + ascending aorta replacement — prevents dissection; upfront cost $15,400–$19,800, essential for survival.
- •Low-income patients (<$3,000/year): ACEi/ARB + biannual echo ($110–$185) — delays surgery while maintaining stability; government subsidy may cover up to 70% of SAVR in public hospitals.
Pricing & Service Differences: International / VIP Dept vs. Regular Clinic
International Medical Services (IMS / VIP Departments) at Grade-3A public hospitals and private international clinics operate under self-regulated VIP fee schedules. Fees are higher than standard public clinics (which are subsidized solely for domestic citizens and do not accept overseas insurances). In exchange, international patients receive 6 exclusive medical privileges:
Recommended Hospitals
Explore selected Grade 3A public hospitals in China with rich clinical experience for this condition:
🌴 Recommended Aortic regurgitation Medical Vacation Packages
Curated transparent all-inclusive packages combining Aortic regurgitation treatment with China top medical destinations:
